Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus.
HIV-exposed uninfected infants
children with HIV
gut integrity
inflammation
translocation
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
23 05 2020
23 05 2020
Historique:
received:
18
03
2019
accepted:
28
06
2019
pubmed:
2
7
2019
medline:
7
1
2021
entrez:
2
7
2019
Statut:
ppublish
Résumé
Children with perinatally acquired human immunodeficiency virus (HIV; PHIVs) face a lifelong cumulative exposure to HIV and antiretroviral therapy (ART). The relationship between gut integrity, microbial translocation, and inflammation in PHIV is poorly understood. This is a cross-sectional study in 57 PHIVs, 59 HIV-exposed but uninfected children, and 56 HIV-unexposed and -uninfected children aged 2-10 years old in Uganda. PHIVs were on stable ART with HIV-1 RNA <400 copies/mL. We measured markers of systemic inflammation, monocyte activation, and gut integrity. Kruskal-Wallis tests were used to compare markers by group and the Spearman correlation was used to assess correlations between biomarkers. The mean age of all participants was 7 years and 55% were girls. Among PHIVs, the mean CD4 % was 34%, 93% had a viral load ≤20 copies/mL, and 79% were on a nonnucleoside reverse transcriptase inhibitor regimen. Soluble cluster of differentiation 14 (sCD14), beta-D-glucan (BDG), and zonulin were higher in the PHIV group (P ≤ .01). Intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide binding protein (LBP) did not differ between groups (P > .05). Among PHIVs who were breastfed, levels of sCD163 and interleukin 6 (IL6) were higher than levels in PHIV who were not breastfed (P < .05). Additionally, in PHIVs with a history of breastfeeding, sCD14, BDG, LBP, zonulin, and I-FABP correlated with several markers of systemic inflammation, including high-sensitivity C-reactive protein, IL6, d-dimer, and systemic tumor necrosis factor receptors I and II (P ≤ .05). Despite viral suppression, PHIVs have evidence of altered gut permeability and fungal translocation. Intestinal damage and the resultant bacterial and fungal translocations in PHIVs may play a role in the persistent inflammation that leads to many end-organ diseases in adults.Despite viral suppression, children with perinatally acquired human immunodeficiency virus (HIV) in Uganda have evidence of alterations in intestinal permeability and fungal translocation, compared to HIV-exposed but uninfected and HIV-unexposed children, which may play a role in HIV-associated chronic inflammation.
Sections du résumé
BACKGROUND
Children with perinatally acquired human immunodeficiency virus (HIV; PHIVs) face a lifelong cumulative exposure to HIV and antiretroviral therapy (ART). The relationship between gut integrity, microbial translocation, and inflammation in PHIV is poorly understood.
METHODS
This is a cross-sectional study in 57 PHIVs, 59 HIV-exposed but uninfected children, and 56 HIV-unexposed and -uninfected children aged 2-10 years old in Uganda. PHIVs were on stable ART with HIV-1 RNA <400 copies/mL. We measured markers of systemic inflammation, monocyte activation, and gut integrity. Kruskal-Wallis tests were used to compare markers by group and the Spearman correlation was used to assess correlations between biomarkers.
RESULTS
The mean age of all participants was 7 years and 55% were girls. Among PHIVs, the mean CD4 % was 34%, 93% had a viral load ≤20 copies/mL, and 79% were on a nonnucleoside reverse transcriptase inhibitor regimen. Soluble cluster of differentiation 14 (sCD14), beta-D-glucan (BDG), and zonulin were higher in the PHIV group (P ≤ .01). Intestinal fatty acid binding protein (I-FABP) and lipopolysaccharide binding protein (LBP) did not differ between groups (P > .05). Among PHIVs who were breastfed, levels of sCD163 and interleukin 6 (IL6) were higher than levels in PHIV who were not breastfed (P < .05). Additionally, in PHIVs with a history of breastfeeding, sCD14, BDG, LBP, zonulin, and I-FABP correlated with several markers of systemic inflammation, including high-sensitivity C-reactive protein, IL6, d-dimer, and systemic tumor necrosis factor receptors I and II (P ≤ .05).
CONCLUSIONS
Despite viral suppression, PHIVs have evidence of altered gut permeability and fungal translocation. Intestinal damage and the resultant bacterial and fungal translocations in PHIVs may play a role in the persistent inflammation that leads to many end-organ diseases in adults.Despite viral suppression, children with perinatally acquired human immunodeficiency virus (HIV) in Uganda have evidence of alterations in intestinal permeability and fungal translocation, compared to HIV-exposed but uninfected and HIV-unexposed children, which may play a role in HIV-associated chronic inflammation.
Identifiants
pubmed: 31260509
pii: 5526740
doi: 10.1093/cid/ciz561
pmc: PMC7245151
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2413-2422Subventions
Organisme : NICHD NIH HHS
ID : K23 HD088295
Pays : United States
Organisme : NIDDK NIH HHS
ID : R21 DK118757
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
J Infect Dis. 2018 Aug 24;218(7):1085-1089
pubmed: 29762690
J Infect Dis. 2017 Sep 15;216(6):651-661
pubmed: 28934432
Nat Med. 2009 Aug;15(8):955-9
pubmed: 19597505
J Infect Dis. 2018 Aug 14;218(6):922-926
pubmed: 29718342
Lancet. 2010 Apr 10;375(9722):1278-86
pubmed: 20347483
Infect Immun. 2001 Nov;69(11):6942-50
pubmed: 11598069
AIDS Res Ther. 2016 Apr 11;13:19
pubmed: 27073405
Clin Biochem. 2003 Oct;36(7):529-35
pubmed: 14563446
Clin Infect Dis. 2011 Apr 1;52(7):953-6
pubmed: 21427404
J Cell Sci. 2000 Dec;113 Pt 24:4435-40
pubmed: 11082037
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
Lancet. 2004 Nov 20-26;364(9448):1865-71
pubmed: 15555666
PLoS One. 2016 May 26;11(5):e0154090
pubmed: 27228093
AIDS Res Hum Retroviruses. 2019 May;35(5):461-472
pubmed: 30784316
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):123-9
pubmed: 27258230
HIV Med. 2013 Jul;14(6):354-61
pubmed: 23332095
PLoS One. 2012;7(8):e42624
pubmed: 22952600
Climacteric. 2005 Dec;8(4):317-26
pubmed: 16390766
Pediatr Infect Dis J. 2012 Jun;31(6):583-91
pubmed: 22333700
Microbiol Immunol. 2011 Sep;55(9):625-32
pubmed: 21699559
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
J Acquir Immune Defic Syndr. 2013 Dec 15;64(5):425-33
pubmed: 23797689
PLoS One. 2015 Apr 15;10(4):e0124599
pubmed: 25874569
Am J Respir Crit Care Med. 2015 Apr 15;191(8):932-42
pubmed: 25603113
Clin Infect Dis. 2019 Apr 8;68(8):1394-1401
pubmed: 30137242
Braz J Med Biol Res. 2008 Aug;41(8):700-8
pubmed: 18797705
Acta Paediatr. 2015 Dec;104(467):3-13
pubmed: 26249674
AIDS. 2013 Nov 13;27(17):2749-58
pubmed: 23842126
AIDS Res Hum Retroviruses. 2015 Aug;31(8):830-6
pubmed: 26059763
PLoS Pathog. 2014 Mar 13;10(3):e1003996
pubmed: 24626467
Atherosclerosis. 2010 Aug;211(2):492-8
pubmed: 20471650
Microbiol Spectr. 2017 Jun;5(3):
pubmed: 28597821
Int J Mol Sci. 2016 Aug 02;17(8):
pubmed: 27490536
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):42-9
pubmed: 23982657
AIDS. 2015 Aug 24;29(13):1617-22
pubmed: 26372272
JAMA Pediatr. 2014 Dec;168(12):1138-46
pubmed: 25286283
Curr Opin HIV AIDS. 2014 Jan;9(1):80-6
pubmed: 24275673
AIDS. 2019 May 1;33(6):1001-1011
pubmed: 30946154
Lancet Infect Dis. 2015 Mar;15(3):327-39
pubmed: 25618179
J Infect Dis. 2013 Dec 1;208(11):1737-46
pubmed: 24041790
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
Sci Rep. 2018 Dec 5;8(1):17679
pubmed: 30518941
AIDS. 2012 Jul 17;26(11):1371-85
pubmed: 22546988
Scand J Gastroenterol. 2008;43(7):831-41
pubmed: 18584522
Med Mal Infect. 2015 Jan-Feb;45(1-2):9-16
pubmed: 25684583
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
Pediatr Infect Dis J. 2017 Aug;36(8):761-767
pubmed: 28067719
J Infect Dis. 2010 Jun 15;201(12):1788-95
pubmed: 20446848
JAMA Pediatr. 2017 Jul 1;171(7):647-654
pubmed: 28492938
Diabetes. 2006 May;55(5):1443-9
pubmed: 16644703
Lancet. 2000 Apr 29;355(9214):1518-9
pubmed: 10801176
Biol Blood Marrow Transplant. 2013 Feb;19(2):329-32
pubmed: 23160005
Sci Transl Med. 2019 Apr 3;11(486):
pubmed: 30944164
Genome Med. 2013 Jul 30;5(7):63
pubmed: 23899327
AIDS. 2019 Apr 1;33(5):845-853
pubmed: 30649056
Clin Sci (Lond). 2016 Aug 1;130(16):1435-51
pubmed: 27389589
N Engl J Med. 2014 Jan 2;370(1):41-53
pubmed: 24382064
J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):242-245
pubmed: 30422903
HIV Med. 2012 May;13(5):264-75
pubmed: 22136114
Curr Opin HIV AIDS. 2018 Jan;13(1):73-80
pubmed: 29045252
J Infect Dis. 2019 Jan 1;219(1):89-100
pubmed: 30107546